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Abstract
Background: Although severe sepsis constitutes an important burden for healthcare systems, there is limited
nationwide data on its epidemiology in European countries. Our objective was to examine the most recent
epidemiological characteristics and trends of severe sepsis in Spain, from a population perspective.
Methods: Analysis of the 2006-2011 National Hospital Discharge Registry. Cases were identified by combining
specific ICD-9CM codes. We estimated demographics, clinical characteristics and outcomes and calculated age- and
sex- adjusted estimations of incidence and mortality rates. Trends were assessed in terms of annual percent change
(APC) in rates using joinpoint regression analysis.
Results: Over the 6-year period we identified 240939 cases of severe sepsis nationwide representing 1.1% of all
hospitalisations and 54% of hospitalisations with sepsis. Incidence was 87 cases per 100,000 population. Overall
58% of cases were men, 66% were over the age of 65 and about 67% had associated comorbidities. Bacteremia
was coded in 16% of records. Almost 54% of cases had one organ dysfunction, 26% two and around 20% three or
more dysfunctions. In-hospital case-fatality was 43% and associated with age, gender, comorbidities and organ
dysfunctions, among others. We found significant demographic and clinical changes over time with an increase in
the mean age of cases, comorbidities, number of organ dysfunctions and in the number of cases with gram-negative
pathogens. Furthermore, even with gender disparities, standardised incidence and mortality rates increased with an
overall APC of 8.6% (95% CI 5.1, 12.1) and 6% (95% CI 1.9, 10.3), respectively. Conversely, we detect a significant decrease
in case-fatality rates with an overall APC of -3.24% (95% CI: -4.2, -2.2).
Conclusions: This nationwide population-based study shows that hospitalizations with severe sepsis are frequent and
associated with substantial in-hospital mortality in Spain. Furthermore it indicates that the incidence and mortality rates
of severe sepsis have notably increased in recent years, showing also a significant increase in the age and severity of
the affected population. Despite this, there has been a significant decreasing trend in case-fatality rates over time. This
information has significant implications for health-care system planning and may prove useful to estimate future care
requirements.
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Background
Severe sepsis is a substantial cause of morbidity and mor-
tality worldwide and associates with high healthcare costs
[1-4]. Recent estimates show that, in developed countries,
severe sepsis is recorded in about 2% of patients admitted
to hospital [1,2], with case-fatality rates ranging from 30%
to 50% [2,4]. Furthermore, epidemiological studies in
the USA have shown a progressive increase in its inci-
dence, in excess of the growth of the population, driving
an increase in the number of deaths [4-8]. Thus, severe
sepsis constitutes both an important clinical and eco-
nomic burden for healthcare systems and a major public
health concern [1-5,9,10].
Despite this, there is limited information on the epi-
demiological characteristics of severe sepsis from a popula-
tion perspective, particularly in Europe [11-13], and most
research comes from intensive care units. However, in
recent years it is more frequently being acknowledged
that a large proportion of cases, between 50% and 70%,
occur outside intensive care units [1,2,14,15] limiting
the extrapolation of results from studies carried out in
this setting to the general population.
On the other hand, to date, most research providing
population-based estimates [4-7] relies on hospital data
samples that are weighted to extrapolate to national-
level estimates and are, therefore, particularly vulnerable
to sampling bias [16]. In this setting, national databases
provide essential tools in epidemiological research of
diseases such as severe sepsis where, on the one hand,
it is impossible to prospectively identify patients at a
nationwide level [1,2,4,16,17] and, on the other, it lacks
the errors that are sometimes present in data obtained
from reduced samples, specific groups, or collected in a
short time period [16]. Consistent estimates of national
incidence, mortality and other epidemiological data are
critical steps for the assessment of the full burden of
severe sepsis [4,5,18]. Besides, temporal data may facili-
tate the detection of trends in epidemiology [5].
Taking this into consideration, we undertook this study
to examine the most recent epidemiological characteristics
and trends of severe sepsis in Spain using the national
registry of hospital discharges.
Methods
Data source
Information regarding hospitalized patients was collected
from the National Minimum Basic Data Set (MBDS). The
MBDS is the official database of the Ministry of Health,
Social Services and Equality and collects demographic and
clinical information on discharge of all acute-care hospital
admissions nationwide. Information is gathered in the
clinical documentation units of each hospital of the
National HealthCare System by trained personnel and
is merged, after a process of validation, into a single
database. The information it provides is considered
to be representative of the national population as it
includes data on over 97% of all annual hospital admis-
sions in our country [19].
National Population data come from the Spanish
National Statistics Institute [20].
Period of analysis
For study purposes we used the national database from
January 1, 2006 to December 31, 2011.
Selection of cases and definitions
Based on prior studies [4-7,18], severe sepsis cases were
identified as the presence, in principal or secondary
diagnoses, of ICD-9CM (International Classification of
Diseases, 9th revision, Clinical Modification) codes for
sepsis and acute organ dysfunction or the presence of
ICD-9CM code 995.92 specific of severe sepsis (systemic
inflammatory response syndrome due to infectious process
with organ dysfunction).
To identify sepsis we employed formerly utilized codes
[5-7] that define infection: 038 (0.38.0 (streptococcal septi-
cemia), 038.1 (staphylococcal septicemia), 038.2 (pneumo-
coccal septicemia), 038.3 (septicemia due to anaerobes),
038.4 (septicemia due to other Gram negative organisms),
038.8 (other specified septicemias), 038.9 (unspecified
septicemia), 003.1 (salmonella septicemia); 020.2 (septi-
cemic plague); 036.2 (meningococcal septicemia); 036.3
(Waterhouse-Friderichsen syndrome); 054.5 (herpetic
septicemia); 098.89 (gonococcemia); 112.5 (systemic
candidiasis); 112.81 (candidal endocarditis); 117.9 (other
and unspecified mycoses); 771.8 ( perinatal infections,
septicaemia of newborn ) and 790.7 (bacteremia). We also
included the ICD-9CM code for sepsis 995.91 (sepsis,
systemic inflammatory response syndrome due to infec-
tious process without organ dysfunction), that became
effective in our country in January 2004 [19].
For acute organ dysfunction we used the following
ICD-9CM codes [5,6,14]: respiratory: 518.81 (acute
respiratory failure), 518.82 (other pulmonary insuffi-
ciency), 518.84 (acute on chronic respiratory failure),
518.85 (acute respiratory distress syndrome after shock or
trauma), 786.09 (respiratory distress, insufficiency), 799.1
(respiratory arrest), 96.7(invasive mechanical ventilation);
cardiovascular: 785.5 with all subcodes (shock without
mention of trauma, includes 785.1, 785.52, 785.9),458
(hypotension, 458.0, 458.8 458.9), 796.3 (nonspecific
low blood pressure reading); renal: 584 with all subcodes
(acute renal failure), 580 (acute glomerulonephritis), 39.95
(hemodialysis); hepatic: 570 (acute and subacute necrosis
of liver), 572.2 (hepatic coma), 573.3 (hepatitis, unspeci-
fied); hematologic: 286.6 (defibrination syndrome), 286.9
(other and unspecified coagulation defects), 287.3-5
(secondary thrombocytopenia, unspecified); neurologic:
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293 (acute delirium), 348.1 (anoxic brain damage), 348.3
(encephalopathy, unspecified), 357.82 (critical illness
polyneuropathy), 780.01 (coma), 780.09 (drowsiness,
unconsciousness, stupor), 89.14 (electroencephalogram)
and metabolic: 276.2 (acidosis metabolic or lactic).
To explore the extent of comorbidities of known prog-
nostic value we used a validated ICD-9CM version of the
Charlson Index [21]. Prior population-based epidemio-
logical studies in sepsis have shown that there is no
overlap between the codes used to calculate this index and
the diagnostic codes used for acute organ dysfunction
[14]. For this study, four different score groups (0, 1-2, 3-4
and > 4) were considered [22].
We defined cases as surgical if they had a major surgi-
cal procedure other than tracheostomy [4] based on the
Diagnosis-related group codes [19].
Ethical aspects
The study was exempt from institutional review board
approval because only de-identified data were used [23].
Data analysis
Initially we conducted a descriptive study to ascertain
demographic characteristics, underlying comorbidities,
Charlson index scores, number and type of organ dys-
functions and case-fatality. Data are summarised as
frequency tables and percentages for categorical variables
and summary statistics (mean ± SE) for continuous vari-
ables. For between-group comparisons, we used the
Snedecor’s F for continuous variables and the χ2 tests for
categorical data. We performed an exploratory logistic
regression analysis to identify factors associated with
in-hospital mortality. Factors that had strong biological
relevance, such as gender, age-group and Charlson index,
or were significantly related to hospital outcomes, such as
the number of organ failures, were included in the model.
Odds ratios (ORs) with 95% confidence intervals were
computed.
Incidence and mortality rates were estimated using
national population data expressing the results per
100000 population. Case-fatality rates (CFR) were cal-
culated as the number of deaths divided by the number
of cases, expressed as a percentage [6,7]. Age and sex-
adjusted rates were calculated by direct methods based
on the European standard population [24]. Age and sex-
adjusted CFR was calculated by direct standardisation
based on the 2008 data.
To identify trends in incidence, mortality and case-
fatality rates we quantified the annual percentage change
(APC) with its respective 95% confidence intervals using
the Joinpoint Regression Program [25]. APC is a widely
used parameter to evaluate trends [26], and we used linear-
log regression models assuming a Poisson distribution for
its estimation [27]. This procedure enables testing whether
an apparent change in trend is statistically significant using
a Monte Carlo permutation method [27].
Statistical analysis was performed using STATA 12
(© 1996–2012 StataCorp LP. TX 77845 USA). P-values
< 0.05 were considered significant.
Results
Out of the 22,070,672 hospital discharges that occurred
in Spain from 2006 to 2011, and after several processes
of verification and depuration of the database, we identi-
fied 240939 overnight hospitalizations with severe sepsis.
General characteristics
Descriptive characteristics of the population are shown
in Table 1. Mean age was 65 years, 66% of episodes
occurred in people ≥ 65 years of age and 58% of cases
were male. Mean Charlson Index score was 1.9. ± 0.004.
Around 67% of cases had underlying comorbidities ran-
ging from 12% in those younger than 18 years to 65% in
18-64 year olds and 75% in those ≥ 65 years of age. Non-
metastatic cancer, chronic obstructive pulmonary disease,
chronic heart failure and chronic renal disorders were,
overall, the most common categories of comorbidity.
Medical diagnostic categories were majority with sur-
gical diagnoses identified in only 26% of cases. A micro-
biological diagnosis of the infection was registered in
61,944 (25.7%) cases. The frequency of the identified
pathogens appears in Table 1, with gram-negative bac-
teria being the most common. Bacteraemia was coded in
39,810 cases.
Around 54% of cases had one organ dysfunction, 26%
experienced two and about 20% three or more dysfunc-
tions. The most frequent dysfunctions were respiratory
(51% of cases), cardiovascular (45%) and renal (40%).
There were 103,461 deaths, which corresponds to a
crude in-hospital case-fatality of 43%. The mean age of
non-survivors was 71.4 ± 0.06 years and the mean Charlson
Index score was 2.2 ± 0.007. As Table 2 shows, mortality
varied with several demographic and clinical characteris-
tics. Bivariate and multivariate analyses are also shown
in Table 2. Adjusted multivariate logistic regression
analysis reveals that the risk of death was significantly
associated with age, severity of comorbidities, the presence
of a subjacent medical diagnostic category, absence of
identified pathogens, and with an increasing number of
failing organs. It also shows that men have a lower risk
of death than women. In addition, homogeneity test
provide evidence that age acts as an effect modifier of
all other covariates (data not shown).
As shown in Table 3, within the study period there have
been several demographic and clinical changes. From 2006
to 2011 the mean age of cases increased significantly both
in men and women related to a clear increase in the
number of cases over the age of 65 years. Likewise, a
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significant increase in the Charlson index score is observed,
as well as an increase in some specific comorbidities and, in
particular, an increase in cases with chronic heart and renal
disorders. Specifically, the percentage of cases with chronic
renal disease doubled during the period of study.
There are also significant changes with time in the
number as well as type of organ dysfunctions. Thus, a
small decrease in the percentage of cases having a sin-
gle dysfunction is seen (55% in 2006, 52% in 2011),
while there is an increase in cases with three or more
dysfunctions (18% in 2006, 22% in 2011). Additionally,
there are significant changes in the type of dysfunctions
being relevant the increasing frequency of renal failure
between 2006 (36%) and 2011 (46% of cases). As
regards to microbiological data, the most striking find-
ing seems to be the decreasing trend of gram-positive
pathogens and the increase of records with gram-
negative bacteria.
As Table 3 shows, within the study period hospital
case-fatality decreased significantly from 45% of cases in
2006 to 40% in 2011. Data also show a relevant decrease
in the length of hospital stay over time.
Incidence, mortality and case-fatality rates
These cases represent 1.1% of national hospitalisations
and 54% of hospitalisations with sepsis from 2006 to 2011.
The overall incidence of severe sepsis was 86.97 cases per
100,000 population. In men, the crude incidence rate was
102.47 cases per 100000 population whereas in women it
was of 71.90 cases per 100000 population.
There have been significant annual changes in inci-
dence over time increasing from 63.91 cases/100000
population in 2006 to 105.51 cases/100000 population
in 2011. The standardised rate increased from 70.86
cases/100000 population in 2006 to 112.11 cases/
100000 population in 2011, with an APC of 8.6% (95%
CI: 5.1, 12.1) (Figure 1).
Figure 1 also shows trends for men and women. In
men, the crude rate has gone from 76.58 cases/100000
population in 2006 to 122.35 cases/100000 population
in 2011. The standardised rate has increased from 95.02
cases/100000 population in 2006 to 147.05 cases/
100,000 population in 2011, with an APC of 8.2% (95%
CI: 4.7, 11.8).
Table 1 General characteristics of the population
(n = 240939)




Mean age (yr) 65.5 ± 0.05
Age-group
<18 y 18093 (7.5)
18-64 y 64764 (26.9)
>64 y 158082 (65.6)
Charlson index
0 points 78665 (32.7)
1-2 points 100530 (41.7)
3-4 points 37901 (15.7)
>4 points 23843 (9.9)
Comorbiditiesa
Cancer (non-metastatic) 41180 (17.1)
Chronic heart failure 34293 (14.2)
Chronic Obstructive Pulmonary Disease 32191 (13.4)
Chronic renal disease 32206 (13.4)
Cerebrovascular disease 20033 (8.3)
Cancer (metastatic) 14313 (5.9)
Acute myocardial infarction 9412 (3.9
Chronic liver disease 8449 (3.5)
Diabetes with complications 6179 (2.6)




















Table 1 General characteristics of the population




Mean length of hospital stay (days) 23 ± 0.06
In-hospital deaths 104461 (43)
Data presented as number of cases and %. aProportions not mutually exclusive.
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For women, the crude incidence rate has gone from
51.52 cases/100000 population in 2006 to 89.12 cases/
100000 population in 2011. The standardised rate has
increased from 51.73 cases/100000 population in 2006
to 84.57 cases/100000 population in 2011, with an APC
of 9.20% (95% CI: 5.8, 12.7).
The overall mortality rate during the study period was
37.1 cases per 100000 population. In men, the crude mor-
tality rate was 43.15 cases per 100000 population whereas
in women, it was of 31.26 cases per 100000 population.
Figure 2 shows that within these years a significant in-
crease in standardised mortality rate has occurred, going
from 32.1 cases in 2006 to 45.3 cases per 100000 popula-
tion in 2011 with an APC of 6% (95% CI: 1.9, 10.3).
Figure 2 also shows the rising trend in standardised
mortality rate in men going from 43.76 cases in 2006 to
59.76 cases/100000 population in 2011 with an APC of
5.4% (95% CI: 1.3, 9.6). In women, the increase was
higher going from 22.95 cases/100000 population in
2006 to 34 cases/100000 population in 2011 with an
APC of 6.97% (95% CI: 2.8, 11.4).
Age- and sex- standardised CFR showed a significant
decrease going from 49.3% in 2006 to 41.9% in 2011 with
an overall APC of -3.5% (95% CI: -4.3, -0.2) (Figure 3). In
men, the standardised rate has gone from 48.71 cases per
100 in 2006 to 40.97 cases/100 in 2011 with an APC
of -3.7% (95% CI:-4.5, -2.9) whereas in women the rate has
gone from 50.34 cases/100 in 2006 to 43.22 cases/100 in
2011 with an APC of -3.24% (95% CI: -4.2, -2.2).
Discussion
To the best of our knowledge this is the first study to
provide nationally population-based representative esti-
mates of the epidemiological characteristics and recent
trends of severe sepsis in Spain. Using information drawn
from all acute-care hospitals nationwide from 2006 to
2011, this study demonstrates the growing burden of
severe sepsis in Spain in recent years with a remarkable
increase in its incidence and mortality rates. On the
other hand, it shows a significant decreasing trend in
case-fatality rates over time despite an increase in the
age and severity of the affected population.
This analysis indicates that severe sepsis represents
1.1% of all hospitalizations in our country within the
study period with an overall incidence rate of 87 cases
per 100,000 population. Although it is well known that
Table 2 In-hospital deaths
Characteristic Cases (%) Case-fatality (% severe sepsis) Bivariate OR (CI 95%) Multivariate OR (CI 95%)
Sex
Men 59424 (57) 42.4 Reference group Reference group
Women 44037(43) 43.7 1.06 (1.04, 1.07) 1.12 (1.10, 1.14)
Age-group
<18 y 3211 (3) 17.8 Reference group Reference group
18-64 y 22588 (22) 34.9 2.48 (2.38, 2.59) 1.56 (1.49, 1.63)
>64 y 77665 (75) 49.1 4.48 (4.30, 4.66) 3.20 (3.06, 3.33)
Charlson index
0 26540 (26) 33.7 Reference group Reference group
1-2 45287 (44) 45.1 1.61 (1.58, 1.64) 1.34 (1.31, 1.37)
3-4 18331 (18) 48.4 1.84 (1.79, 1.89) 1.57 (1.52, 1.61)
>4 13306 (13) 55.8 2.48 (2.41, 2.55) 2.58 (2.50, 2.66)
Diagnostic categories
Surgical 27655 (26.7) 44.4 Reference group Reference group
Medical 75809 (73.3) 42.4 0.93 (0.91, 0.94) 1.03 (1.01, 1.06)
Identified pathogens
No 40151 (78.9) 45.6 Reference group Reference group
Yes 21793 (21.1) 35.2 0.65 (0.63, 0.66) 0.63 (0.62, 0.65)
No. of organ system dysfunctions
1 43023 (41.6) 33.4 Reference group Reference group
2 29712 (28.7) 47.3 1.78 (1.75, 1.82) 1.88 (1.84, 1.92)
≥3 30729 (29.7) 62.6 3.34 (3.26, 3.41) 3.89 (3.80, 3.98)
General characteristics, case-fatality and risk.
OR, odds ratio; CI 95%, 95% confidence interval.
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Table 3 Characteristics of the episodes of severe sepsis: Sequential data from 2006 to 2011
2006 2007 2008 2009 2010 2011
Men 59.2% (58.7, 59.8) 58.8% (58.3, 59.3) 58.4% (57.9, 58.9) 58.4% (57.9, 58.8) 57.8%(57.3, 58.3) 57.2% (56.8, 57.7)
Age 62.7 ± 0.15 63.9 ± 0.13 64.6 ± 0.12 65.7 ± 0.11 67.0 ± 0.11 67.6 ± 0.10
Men 61.2 ± 0.19 62.6 ± 0.16 63.2 ± 0.16 64.5 ± 0.14 65.9 ± 0.14 66.1 ± 0.13
Women 64.8 ± 0.23 65.7 ± 0.19 66.7 ± 0.17 67.5 ± 0.16 68.5 ± 0.17 69.5 ± 0.16
Age groups
<18 y 9.7% (9.4, 10.0) 8.6% (8.3, 8.9) 8.1% (7.9, 8.4) 7.3% (7.1, 7.5) 6.6% (6.3, 6.8) 6% (5.8, 6.3)
18-64 y 28.5% (28.0, 29.0) 28.1% (27.6, 28.6) 27.7% (27.3, 28.1) 26.8% (26.4, 27.2) 25.6% (25.2, 26.0) 25.7% (25.3, 26.0)
>64 y 61.8% (61.2, 62.4) 63.3% (62.8, 63.8) 64.2% (63.7, 64.6) 65.9% (65.5, 66.3) 67.8% (67.4, 68.2) 68.3% (67.9, 68.7)
Diagnostic categories
Medical 75.3% (74.8, 75.8) 75.1%(74.7, 75.6) 72.8%(72.3, 73.2) 73.1% (72.7, 73.5) 74.1% (73.7, 74.5) 74.8% (74.4, 75.2)
Surgical 24.7% (24.2, 25.2) 24.9%(24.4, 25.3) 27.2% (26.8, 27.7) 26.9% (26.5, 27.3) 25.9% (25.5, 26.3) 25.2% (24.8, 25.6)
Charlson index 1.76 ± 0.01 1.73 ± 0.01 1.84 ± 0.01 1.90 ± 0.01 1.91 ± 0.01 1.95 ± 0.01
Comorbidities
Cancer (non-metastatic) 17.0% (16.6, 17.4) 16.8%(16.4, 17.2) 16.7% (16.3, 17.1) 17% (16.6, 17.4) 17.2% (16.8, 17.5) 17.7% (17.3, 18.0)
COPDa 12.9% (12.5, 13.3) 13.2%(12.8, 13.6) 13.4% (13.1, 13.7) 13.9% (13.6, 14.2) 13.3% (13.0, 13.7) 13.2% (12.9, 13.5)
Chronic cardiac failure 12.5% (12.1, 12.9) 13.1% (12.8, 13.5) 13.9% (13.5, 14.2) 14.6% (14.3, 14.9) 14.9% (14.5, 15.2) 15.4% (15.1, 15.7)
Chronic renal disease 8.8% (8.5, 9.2) 8.8% (8.5, 9.1) 13.3% (13.0, 13.6) 14.9% (14.5, 15.2) 15.4% (15.0, 15.7) 16.1% (15.8, 16.4)
Cerebrovascular 8.4% (8.1, 8.8) 8.1% (7.8, 8.4) 8.3% (8.0, 8.5) 8.4% (8.0, 8.5) 8.4% (8.1, 8.6) 8.3% (8.1, 8.6)
Cancer with metastasis 5.6% (5.3, 5.9) 5.5% (5.3, 5.7) 5.7% (5.4, 5.9) 5.8% (5.6, 6.1) 6.3% (6.1, 6.5) 6.4% (6.2, 6.6)
Number of organ dysfunctions
1 55.1% (54.5, 55.6) 54.1% (53.6, 54.7) 53.9% (53.4, 54.3) 53.1% (52.6, 53.5) 53.9% (53.4, 54.3) 52.0% (51.6, 52.4)
2 26.8% (26.3, 27.3) 26.2% (25.7, 26.7) 25.9% (25.5, 26.3) 26.1% (25.6, 26.5) 25.5% (25.1. 25.9) 26.4% (26.0, 26.8)
≥3 18.2% (17.7, 18.6) 19.7% (19.3, 20.1) 20.3% (19.9, 20.6) 20.9% (20.5, 21.3) 20.7% (20.3, 21.0) 21.6% (21.3, 22.0)
Type of organ dysfunctionb
Respiratory 51.9% (51.4, 52.5) 52.3% (51.8, 52.8) 51.6% (51.1, 52.1) 51.6% (51.1, 52.0) 48.9% (48.4, 49.4) 47.7% (47.3, 48.1)
Cardiovascular 45.9% (45.3, 46.4) 47.0% (46.5, 47.5) 45.9% (45.4, 46.4) 44.4% (44.0, 44.9) 43.9% (43.4, 44.3) 42.8% (42.3, 43.2)
Renal 36.5% (36.0, 37.1) 37.0% (36.5, 37.6) 38.2% (37.7, 38.6) 40.1% (39.6, 40.5) 41.7% (41.3, 42.2) 46.5% (46.1, 47.0)
Hepatic 5.3% (5.1, 5.6) 5.2% (5.0, 5.5) 5.4% (5.2, 5.7) 5.4% (5.2, 5.7) 5.1% (4.9, 5.3) 4.9% (4.7, 5.1)
Metabolic 7.4% (7.1, 7.7) 7.2% (7.0, 7.5) 7.8% (7.5, 8.0) 8.7% (8.4, 8.9) 8.7% (8.5, 9.0) 9.4% (9.1, 9.6)
Neurologic 10.6% (10.3, 11.0) 10.6% (10.3, 11.0) 10.8% (10.5, 11.1) 11.2% (10.9, 11.5) 11.1% (10.8, 11.4) 11.2% (11.0, 11.5)
Hematolologic 11.1% (10.7, 11.5) 11.0% (10.7, 11.4) 11.8% (11.5, 12.1) 11.8% (11.5, 12.1) 11.9% (11.6, 12.2) 12.4% (12.1, 12.7)
Identified Germsb
Yes 26.9% (26.4, 27.4) 25.6% (25.1, 26.0) 25.4% (25.0, 25.8) 24.8% (24.4, 25.2) 25.8% (25.4, 26.2) 26.1% (25.8, 26.5)
Gram positive 39.4% (38.4, 40.5) 39.2% (38.2, 40.3) 39.1% (38.2, 40.1) 37.3% (36.4, 38.3) 35.1% (34.3, 36.0) 33.6% (32.8, 34.4)
Gram-negative 56.3% (55.2, 57.4) 56.3% (55.2, 57.3) 58.1% (57.1, 59.0) 59.2% (58.3, 60.1) 62.4% (61.5, 63.3) 64.5% (63.7, 65.4)
Anaerobic 1.5% (1.2, 1.8) 1.5% (1.3, 1.8) 1.4% (1.2, 1.7) 1.7% (1.5, 2.0) 1.5% (1.3, 1.8) 1.8% (1.6, 2.0)
Fungus 9.4% (8.7, 10.0) 8.7% (8.1, 9.3) 7.4% (6.9, 7.9) 7% (6.5, 7.5) 6.8% (6.3, 7.2) 6.1% (5.8, 6.6)
Bacteremia 18% (17.6, 18.5) 16.4% (16.0, 16.8) 16.2% (15.9, 16.6) 16.4% (16.0, 16.7) 16.2% (15.9, 16.6) 16.4% (16.0, 16.7)
Length of stay (days) 24.8 ± 0.19 24.5 ± 0.17 24.1 ± 0.16 23.1 ± 0.14 21.9 ± 0.13 21.0 ± 0.12
Case-fatality 45.4% (44.9, 46.0) 45.9% (45.4, 46.5) 43.6% (43.1, 44.1) 42.9% (42.5, 43.4) 41.5% (41.0, 41.9) 40.2% (39.8. 40.6)
aChronic Obstructive Pulmonary Disease. bProportions not mutually exclusive.
Data presented as % of cases (with its corresponding 95% Confidence Interval) or mean ± SE.






















































Figure 1 Number of cases and age-adjusted national incidence of severe sepsis in Spain from 2006 to 2011. The data correspond to the
annual number of cases (plot 1a) and the age-adjusted standardized incidence rates (plot 1b) for the whole population of severe sepsis and for men
and women in a specific manner. Rates were calculated by direct methods based on the European standard population. For the entire population,
cases raised from 28579 in 2006 to 49782 in 2011. The standardised rate increased from 70.86 in 2006 to 112.11 cases/100000 population in 2011. In
men (central section), cases have gone from 16927 in 2006 to 28488 in 2011. The standardised rate has increased from 95.02 cases/100000 population
in 2006 to 147.05 cases/100000 population in 2011. In women, cases have gone from 11651 to 21293 and the standardised incidence rate has
increased from 51.73 cases/100000 population in 2006 to 84.57 cases/100000 population in 2011.















































Figure 2 Number of deaths and age-adjusted standardized mortality rates. The data represent, for the entire population of severe sepsis
and for men and women in a specific manner, the annual number of deaths (plot 2a) and the age-adjusted standardized mortality rates (plot 2b).
Rates were calculated by direct methods based on the European standard population. For the entire population the number of deaths raised
from 12988 cases in 2006 to 20012 in 2011, whereas the standardised mortality rate has gone from 32.1 cases in 2006 to 45.3 cases per 100000
population in 2011. In men, the number of deaths increased from 7650 to 11290 and the standardised mortality rate went from 43.76 cases in
2006 to 59.76 cases/100000 population in 2011. In women (5338 deaths in 2006, 8722 in 2011), the increase was higher going from 22.95 cases/
100000 population in 2006 to 34 cases/100000 population in 2011 (right section).
Bouza et al. BMC Infectious Diseases 2015, 14:717 Page 8 of 13
http://www.biomedcentral.com/1471-2334/14/717
there is a substantial worldwide variability in the occur-
rence of severe sepsis [18], our figures are close to those
found in related studies from the USA [5-7] and Australia
[14]. Also, the incidence rate is in accordance with
the estimation of 50-100 cases per 100,000 population
recently reported for developed countries [2].
Comparison with similar Spanish studies, while local,
show that our figure is greater than that observed in the
Community of Valencia between 1995 and 2004 [13] but
lower than those described in two studies in the Region
of Madrid [12,28]. In one of these studies, we docu-
mented a rate of 141 cases per 100,000 population in
2001 [12]. However, that study was limited to a single
year and to a very specific region where large hospitals
concentrate, which could explain fairly well the dif-
ferences encountered. Our present work estimates the
national incidence and allows us to know the extent
and impact of severe sepsis nationwide overcoming the
limitations of local data.
Our results also demonstrate that from 2006 to 2011
the standardised incidence rate experienced an upward
trend with an annual increase of 8.6%. Though the inter-
pretation of this increasing trend is not easy and may be
in part confounded by factors such a greater awareness
of severe sepsis, the introduction of specific ICM-9
codes that facilitate its coding in medical records, or
other methodological issues [29], there are possible rea-
sons for a real rise in the incidence of severe sepsis includ-
ing, among others, the increased age and comorbidities of
the population and the greater use of invasive procedures
and immunosuppressive drugs [1,2,5]. Indeed, factors
related to this increase remain an open question that
our study is unable to resolve but our figure is rather
close to that described by authors such as Martin [5]
and Dombrosvky in the USA [7]. In addition, other
Spanish studies, although not focused on severe sepsis,
have observed a clear rise in sepsis hospitalizations in
the last few years [13,28].
As for the demographic and clinical characteristics,
our results agree, in general, with international data.
Thus, we find that severe sepsis is more common in
men [4-6], who also develop it at an earlier age than
women. Though the explanation for this finding re-
mains uncertain, it is in agreement with Martin’s report
[5] where men were 4-6 years younger than women.
Additionally, almost two thirds of the cases are over the
age of 65, with a similar percentage presenting under-
lying comorbidities [4,7,14] and regarding the number
of organ failures, our results are similar to those found
in international literature where about 58%-81% of cases
of severe sepsis present one organ dysfunction and just
6%-16% show three or more [4,7,8].
Microbiological data indicate that less than a third of
the cases have identified pathogens, with bacteremias
coded in 16% of cases overall. Though it has to be recog-
nized that national databases may fail to depict these
data accurately, our figures fully agree with that ob-
served in a recent study from our country [15]. In this
prospective but short-term study performed in 2003 at
three hospitals in Madrid only 29% (95% CI 25-32) of
microbiological samples were positive, whereas a total of
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Figure 3 Age-adjusted case-fatality rates of Severe Sepsis from 2006 to 2011. Changes with time in case-fatality rate (CRF) by 100 episodes
of severe sepsis. Overall rate (solid line), data in men (long-dash), data in women (short-dash). Age- and sex- standardised CFR showed a significant
decrease over time going from 49.3 per 100 in 2006 to 41.9 in 2011. In men, the standardised rate has gone from 48.71 cases per 100 in 2006
to 40.97 cases/100 in 2011 whereas in women the rate has gone from 50.34 cases/100 in 2006 to 43.22 cases/100 in 2011.
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As regards to the causative organisms, Gram-negative
bacteria were the most frequently involved microorganisms
and there was a remarkable increase in the number of
these organisms from 2006 to 2011. Though these findings
could differ from the common literature that indicates that
gram-positive organisms have become the most common
cause of sepsis in the past 25 years [2,5], they are in line
with more recent data [1] and fully agree with those found
in other studies in our country. In fact, our results confirm
the microbiological profile found by Esteban et al in
Madrid in 2003 [15] and the rising trend of sepsis
caused by gram-negative bacteria found by Andreu et al
in the Region of Valencia from 1995 to 2004 [13].
Additionally, our analysis shows that, over the study
period, cases of severe sepsis occur in older people,
who have more comorbidities and develop a greater
number of organ failures. These changes, similar to
those described in reputable USA studies [5,7], seem to
reflect the ageing and chronic morbidity of western
societies [30] and paint a picture of greater frailty and
severity of disease over time.
As previously reported [4-7,14,31,32], age, comorbidi-
ties and the number of organ dysfunctions are factors
significantly associated with the risk of in-hospital death
in our cases. However, our fatality close to 43% is high,
greater than the 21%-33% described in older studies
[4,11,12,14] or in local studies performed during a very
short period [15]. Nevertheless, comparisons with recent
studies from our country show that our rate agree with
the 42.5% reported by Andreu [13] in the Region of
Valencia between 1995 and 2004, and with the results
of Ayala-Rodriguez [28] (40% in men, 39% in women) in
the region of Madrid between 2003 and 2011. Although
we realize that we cannot entirely rule out the possibility
that the cases diagnosed as severe sepsis are the most
critical cases for which mortality rates are higher
[13,33], nor exclude that withholding or withdrawing of
treatments have occurred, our figures are visibly lower
than those recently reported in the ICU setting [34,35].
Additionally, our results show a significant decreasing
trend in case-fatality rates with an average decrease of
3.5% per year from 2006 to 2011, a pattern that, in the
above depicted setting of greater age and frailty of the
affected population, we consider particularly important.
These data add to the most recent literature showing a
decreasing trend of case-fatality in severe sepsis despite
a substantial increase in the number of deaths related to
the process [5-8], a finding that our study also confirms.
As regards case-fatality rates, Dombrovsky reported
annual decreases of 1.4% between the years 1993 and
2003 [6] whereas Lagu observed an average annual decline
in adults of 2% from 2003 to 2007 [8]. Our rate of decline
is somewhat higher, but differences in the populations an-
alyzed and the methodology used for estimation of
trends, joinpoint regression in our work, may at least
partially explain the differences. We must also recognize
that notable educational clinical initiatives promoting
best practices in the management of severe sepsis have
been developed in recent years in Spain [36], which
quite possibly have been beneficial in reducing our
case-fatality over time.
Lastly, a finding we consider remarkable in our ana-
lysis is the gender-related disparities in the incidence
and mortality of severe sepsis. In our study, although
women suffer less from severe sepsis than men, trend
analysis showed a higher increase in both incidence
and mortality rates from 2006 to 2011. Additionally,
joinpoint analysis showed a lower decline of CFR in
women than in men. Prior studies have also found simi-
lar disparities [4-6], but the possible impact of gender
in the incidence and outcome of severe sepsis is a
highly controversial topic and the reasons for these
differences remain unclear [37,38]. Although, in our
study, age could play an important role, these dispar-
ities require a more in depth and detailed analysis
which we are in the process of carrying out.
Among the strengths of this study we can emphasize
its nationwide nature. While there is not national sur-
veillance for severe sepsis in Spain, this study captures
all acute-care, public and private, hospitalisations nation-
wide and serves as an adequate proxy. The data source
used is considered the main information source to carry
out epidemiological studies and health services research
in our country as it includes data on over 97% of all
annual hospital admissions [19]. To avoid errors due to
changes in the ICD9-CM system we chose a period
where the selected codes for severe sepsis, including the
codes 995.92 and 995.91 that became effective in our
country in 2004, suffered no change. Furthermore, the
joinpoint regression used for analysis is a robust, widely
used and validated methodology to evaluate trends.
Moreover, we followed the guidelines for reporting
observational studies, as outlined by the STROBE
Initiative [39]. Thus, we firmly believe this study pro-
vides potentially robust data on the characteristics and
impact of severe sepsis in our country. This informa-
tion can be useful in the design and application of edu-
cational and therapeutic programmes to promote the
early identification and treatment of patients with
severe sepsis that can improve the quality of healthcare
and enable a cost-effective use of health resources. At
the same time, our data represent a fundamental work-
ing basis to evaluate the impact of severe sepsis in our
country and estimate future needs.
These data are complementary to recent reports of
trends in severe sepsis epidemiology published in North
America and might be useful in other European coun-
tries with a population similar to ours.
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We must also acknowledge possible limitations of our
work. This study is subject to the limitations inherent in
retrospective studies using administrative databases.
Data from these databases lack of many measures ob-
tainable only from chart review. Furthermore, these
data do not allow causal inferences to be made. Con-
cerning the potential risk for bias based on coding prac-
tices although we recognize that the study would be
enhanced by clinical validation of diagnostic codes,
access to clinical histories in our country is restricted by
law [40,41] and these may not be consulted where the
aim is research, even if it is epidemiological in nature.
However, the use of such databases is well-established
in severe sepsis epidemiology [4-8,11-15,42] and has
been shown to furnish valuable information for asses-
sing the need for preventive and therapeutic care and
for service planning [16-18,43]. Further, the results of a
recent meta-analysis clearly support the use of admi-
nistrative data to monitor mortality trends in severe
sepsis [43], reassuring the essential role of a consistent
use of national administrative data for epidemiological
monitoring of incidence and outcomes [18]. Addition-
ally, the chief advantage of the hospital discharge data-
base that underpins this study is that information is
recorded by specialised medical coders based on a
detailed review of the medical chart, increasing the like-
lihood of accurate documentation [44], and we must
emphasize that quality assurance audits are systematically
conducted on this national database to verify the adequacy
of coding [19].
However, it should be recognized that although the
use of ICD-9 codes has been shown to be highly sensi-
tive for severe sepsis [18], the extracting coding strategy
is not standardized and inconsistencies between various
methods remain [18,29,33]. Different algorithms used to
identify severe sepsis cases in administrative data, select
cases of varying disease severity sometimes resulting in
estimates, with low specificity, which tend to underre-
present the real cases of severe sepsis [29]. With this
data in mind, to carry out this study we have selected
and used the combination of infection and organ dys-
function codes initially described by Martin [5], and
later extended by Dombrosky et al. [6,7] after the intro-
duction of the new ICD-9 criteria-specific codes for
sepsis, severe sepsis and septic shock. The codes
employed by Martin et al [5] have shown a high specifi-
city for capturing severe sepsis cases [18,29], with a
positive predictive value of 97.7% [42]. In addition,
code 995.92 has a specificity close to 100% [33]. How-
ever, as recent publications [18,33] point out, the use of
this code is limited and not recommended as a single
code for the estimation of national data, but most
always be combined with ICD-9 codes for infection
plus organ dysfunction. Given the codes selected and
the results achieved, both with respect to the incidence
and mortality rates as well as case-fatality, we are
confident that the cases included in our study are truly
severe sepsis cases and not milder conditions.
Eventually our study may be limited by the changes in
the ICD-9 system that have taken place in the last few
years. Similar to what other authors believe [5,7,8], we
should consider the possibility that these changes in the
ICD-9 system may have had an influence in the data and
trends observed. However, as explained above, we chose
a period where the selected codes for severe sepsis
suffered no change in our country. In addition, the
joinpoint analysis shows a progressive increase in the
respective annual percentage changes with no inflec-
tion points, suggesting that the potential changes in
coding have had little effect.
Lastly, we must recognize that the restriction of
the study to hospitalized patients may have introduced
a bias, as Linde-Zwirble [42] points out, and our esti-
mates of incidence rates of severe sepsis really corres-
pond to treated incidence. In line with this, the figures
of mortality associated to severe sepsis refer to hospi-
talized cases. A recent publication by McPherson et al.
that analyses the mortality database from the National
Statistics Office using the ICD-10 coding systems,
points out that in England, between 2001 and 2010,
93.4% of all deaths associated to sepsis occurred within
hospitals, while the remaining 6.6% took place outside
hospitals [45]. We do not know whether the same
occurs in our country, but it is possible that our
estimates are conservative and underestimate the
impact of severe sepsis in our population and our health
system.
Conclusions
This study provides, from a population perspective, the
first nationally representative estimate of the characteris-
tics and recent trends of severe sepsis in Spain. The ana-
lysis, from 2006 to 2011, of the nationwide hospital
discharge database indicate the growing burden of severe
sepsis in these years with a remarkable increase in its
incidence and mortality rates over time. On the other
hand, our data show a significant decreasing trend in
case-fatality rates despite an increase in the age and
severity of the affected population. There are, however,
disparities in several outcomes based on both age and
gender.
We believe this study provides potentially robust data
on the epidemiology and impact of severe sepsis in our
country. This information has significant implications
for health-care service planning and may prove useful to
estimate future care requirements. Additionally, it might
be useful in other European countries with a population
similar to ours.
Bouza et al. BMC Infectious Diseases 2015, 14:717 Page 11 of 13
http://www.biomedcentral.com/1471-2334/14/717
Abbreviations
APC: Annual percent change; MBDS: National minimum basic data set;
ICD-9CM: International classification of diseases, 9th revision, clinical
modification; ORs: Odds ratios; CFR: Case-fatality rates; COPD: Chronic
obstructive pulmonary disease.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and design: CB, TLC. Collection and assembly of the data: CB,
TLC, ZSP, JMA. Analysis and interpretation of the data: CB, TLC,ZSP, JMA.
Statistical expertise: TLC. Drafting of the manuscript: CB, TLC. All authors read
and approved the manuscript before submission.
Acknowledgements
Funding for this study was provided by the Spanish National I + D Program
(grant number STPY 1346/09). The funding body had no further role in study
design, data collection, analysis, interpretation, writing of the report, or the
decision to submit the paper for publication.
We especially thank the Subdirección General de Información Sanitaria e
Innovación (MSSI) for providing the data used in this study.
Received: 24 October 2014 Accepted: 15 December 2014
References
1. Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med
2013, 369:840–851.
2. Martin GS: Sepsis, severe sepsis and septic shock: changes in incidence,
pathogens and outcome. Expert Rev Anti Infect Ther 2012, 10:701–706.
3. Iwashyna TJ, Ely EW, Smith DM, Langa KM: Long-term cognitive impairment
and functional disability among survivors of severe sepsis. JAMA 2010,
314:1787–1794.
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR:
Epidemiology of severe sepsis in the United States: analysis of incidence,
outcome, and associated costs of care. Crit Care Med 2001, 29:1303–1310.
5. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in
the United States from 1979 through 2000. N Engl J Med 2003,
348:1546–1554.
6. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL: Facing the challenge:
decreasing case fatality rates in severe sepsis despite increasing
hospitalizations. Crit Care Med 2005, 33:2555–2562.
7. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL: Rapid increase in
hospitalization and mortality rates for severe sepsis in the United States:
a trend analysis from 1993 to 2003. Crit Care Med 2007, 35:1244–1250.
8. Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK:
Hospitalizations, costs, and outcomes of severe sepsis in the United
States 2003 to 2007. Crit Care Med 2012, 40:754–761.
9. Hall MJ, Williams SN, DeFrances CJ, Golosinskiy A: Inpatient care for
septicaemia or sepsis: a challenge for patients and hospitals. NCHS Data
Brief 2011, 62:1–8.
10. Angus DC: The lingering consequences of sepsis: a hidden public health
disaster? JAMA 2010, 304:1833–1834.
11. Flatten H: Epidemiology of sepsis in Norway in 1999. Crit Care 2004,
8:R180–R184.
12. Iñigo J, Sendra JM, Diaz R, Bouza C, Sarría-Santamera A: Epidemiología y
costes de la sepsis grave en Madrid. Estudio de altas hospitalarias. Med
Intensiva 2006, 30:197–203.
13. Andreu Ballester JC, Ballester F, González Sánchez A, Almela Quilis A,
Colomer Rubio E, Peñarroja Otero C: Epidemiology of sepsis in the
Valencian Community (Spain), 1995-2004. Infect Control Hosp Epidemiol
2008, 29:630–634.
14. Sundararajan V, Macisaac CM, Presneill JJ, Cade JF, Visvanathan K:
Epidemiology of sepsis in Victoria, Australia. Crit Care Med 2005, 33:71–80.
15. Esteban A, Frutos-Vivar F, Ferguson ND, Peñuelas O, Lorente JA, Gordo F,
Honrubia T, Algora A, Bustos A, Garcia G, Diaz-Regañon IR, de Luna RR:
Sepsis incidence and outcome: contrasting the intensive care unit with
the hospital ward. Crit Care Med 2007, 35:1284–1289.
16. Rubenfeld GD, Angus DC, Pinsky MR, Curtis JR, Connors AF Jr, Bernard GR:
Outcomes research in critical care: results of the American Thoracic
Society Critical Care Assembly Workshop on Outcomes Research. Am J
Respir Crit Care Med 1999, 160:358–367.
17. Lawrenson R, Williams T, Farmer R: Clinical information for research: the
use of general practice databases. J Public Health Med 1999, 21:299–304.
18. Gaieski DF, Edwards JM, Kallan MJ, Carr BG: Benchmarking the incidence
and mortality of severe sepsis in United States. Crit Care Med 2013,
41:1167–1174.
19. Sistema de Información Sanitaria Servicio Nacional de Salud. Ministerio
de Sanidad. [http://www.msssi.gob.es/estadEstudios/estadisticas/
sisInfSanSNS/tablasEstadisticas/home.htm]
20. Instituto Nacional de Estadística. [http://www.ine.es/]
21. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for
use with ICD-9-CM administrative databases. J Clin Epidemiol 1992,
45:613–619.
22. Librero J, Peiró S, Ordiñana R: Chronic comorbidity and outcomes of
hospital care: length of stay, mortality and readmission at 30 and
365 days. J Clin Epidemiol 1999, 52:171–179.
23. Law14/2007, of 3 July, on Biomedical Research. [www.boe.es]
24. Eurostat. Revision of the European Standard Population Report of
Eurostat’s task force. 2013 edition; Luxembourg: European Commission
[http://epp.eurostat.ec.europa.eu].
25. Joinpoint Regression Program. Version 3.5.1. July 2011; Statistical
Methodology and Applications Branch and Data Modeling Branch,
Surveillance Research Program National Cancer Institute. US.gov
[http://www.srab.cancer.gov.joinpoint]
26. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK: Estimating average
annual percent change in trend analysis. Stat Med 2009, 28:3670–3678.
27. Kim HJ, Fay MP, Feuer EJ, Midthune DN: Permutation tests for
joinpoint regression with applications to cancer rates. Stat Med 2000,
19:335–351.
28. Ayala-Ramírez OH, Domínguez-Berjón MF, Esteban-Vasallo MD: Trends in
hospitalizations of patients with sepsis and factors associated with
inpatient mortality in the Region of Madrid, 2003-2011. Eur J Clin
Microbiol Infect Dis 2014, 33:411–421.
29. Wilhelms SB, Huss FR, Granath G, Sjöberg F: Assessment of incidence of
severe sepsis in Sweden using different ways of abstracting International
Classification of Diseases codes: difficulties with methods and
interpretation of results. Crit Care Med 2010, 38:1442–1449.
30. Milbrandt EB, Eldadah B, Nayfield S, Hadley E, Angus DC: Toward an
integrated research agenda for critical illness in aging. Am J Respir Crit
Care Med 2010, 182:995–1003.
31. Martin GS, Mannino DM, Moss M: The effect of age on the development
and outcome of adult sepsis. Crit Care Med 2006, 34:15–21.
32. Esper AM, Moss M, Lewis CA, Nisbet R, Mannino DM, Martin GS: The role of
infection and comorbidity: factors that influence disparities in sepsis.
Crit Care Med 2006, 34:2576–2582.
33. Whittaker SA, Mikkelsen ME, Gaieski DF, Koshy S, Kean C, Fuchs BD: Severe
sepsis cohorts derived from claims-based strategies appear to be biased
toward a more severely ill patient population. Crit Care Med 2013,
41:945–953.
34. Blanco J, Muriel-Bombín A, Sagredo V, Taboada F, Gandía F, Tamayo L, et al:
Incidence, organ dysfunction and mortality in severe sepsis: a Spanish
multicentre study. Crit Care 2008, 12:R158. doi:10.1186/cc7157.
35. Dreiher J, Almog Y, Sprung CL, Codish S, Klein M, Einav S, et al: Temporal
trends in patient characteristics and survival of intensive care admissions
with sepsis: a multicenter analysis. Crit Care Med 2012, 40:855–860.
36. Ferrer R, Artigas A, Levy MM, Blanco J, González-Díaz G, Garnacho-Montero
J, et al: Improvement in process of care and outcome after a multicenter
severe sepsis educational program in Spain. JAMA 2008, 299:2294–2303.
37. Angus DC, Burgner D, Wunderink R, Mira JP, Gerlach H, Wiedermann CJ, et
al: The PIRO concept: P is for predisposition. Crit Care 2003, 7:248–251.
38. Adrie C, Azoulay E, Francais A, Clec’h C, Darques L, Schwebel C, et al:
Influence of gender on the outcome of severe sepsis: a reappraisal. Chest
2007, 132:1786–1793.
39. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke
JP, et al: Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement: guidelines for reporting
observational studies. BMJ 2007, 335:806–808.
40. Ley Orgánica 15/1999 de 13 de Diciembre de Protección de Datos de
Carácter personal. Boletín Oficial del Estado. [www.boe.es/buscar/doc.
php?id=BOE-A-1999-23750]
Bouza et al. BMC Infectious Diseases 2015, 14:717 Page 12 of 13
http://www.biomedcentral.com/1471-2334/14/717
41. Ley 41/2002, de 14 noviembre, ley básica reguladora de la autonomía
del paciente y de derechos y obligaciones en materia de información y
documentación clínica. Boletín Oficial del Estado n° 274, de 15-11-2002.
[www.msssi.gob.es]
42. Linde-Zwirble WT, Angus DC: Severe sepsis epidemiology: sampling,
selection, and society. Crit Care 2004, 8:222–226.
43. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ: Two
decades of mortality trends among patients with severe sepsis: a
comparative meta-analysis. Crit Care Med 2014, 42:625–631.
44. Wilchesky M, Tamblyn RM, Huang A: Validation of diagnostic codes within
medical services claims. J Clin Epidemiol 2004, 57:131–141.
45. McPherson D, Griffiths C, Williams M, Baker A, Klodawski E, Jacobson B, et al:
Sepsis-associated mortality in England: an analysis of multiple cause of
death data from 2001 to 2010. BMJ Open. 2013, 3:e002586. doi:10.1136/
bmjopen-2013-002586.
doi:10.1186/s12879-014-0717-7
Cite this article as: Bouza et al.: Epidemiology and recent trends of
severe sepsis in Spain: a nationwide population-based analysis (2006-
2011). BMC Infectious Diseases 2015 14:717.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bouza et al. BMC Infectious Diseases 2015, 14:717 Page 13 of 13
http://www.biomedcentral.com/1471-2334/14/717
